Key result
Administration of 500 mg acetylsalicylic acid twice daily inhibited platelet aggregation in 100% (38/38) of patients with prostate carcinoma treated with estrogens.
Why the study?
Does acetylsalicylic acid reduce platelet aggregation in patients with carcinoma of the prostate treated with estrogens?
Does acetylsalicylic acid reduce platelet aggregation in patients with carcinoma of the prostate treated with estrogens?
Acetylsalicylic acid 500 mg twice daily effectively inhibits platelet aggregation in prostate cancer patients treated with estrogens, suggesting a potential role in reducing cardiovascular and thromboembolic complications.
Aspirin may mitigate estrogen-related platelet hyperaggregability in prostate cancer; level 5 data leaves open randomized confirmation before practice change.
Platelet aggregation is increased in patients with carcinoma of the prostate treated with estrogens. Hence, these patients have a high incidence of cardiovascular and thromboembolic diseases. Platelet aggregation has been tested with the platelet aggregation test. It was inhibited by administration of 500 mg. acetylsalicylic acid twice daily. An aggregation inhibiting effect has been found in all 38 patients. To reduce the excess hazards of cardiovascular complications of estrogens in treating carcinoma of the prostate acetylsalicylic acid is recommended as an adjunct therapy.
No takes yet. Share an insight, caveat, or question.
Eisen et al. (1975) studied Carcinoma of the prostate treated with estrogens (n=38). Acetylsalicylic acid was evaluated on Platelet aggregation inhibition. Administration of 500 mg acetylsalicylic acid twice daily inhibited platelet aggregation in 100% (38/38) of patients with prostate carcinoma treated with estrogens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: